Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder

被引:64
作者
Ganne, V
Siddiqi, N
Kamaplath, B
Chang, CC
Cohen, EP
Bresnahan, BA
Hariharan, S
机构
[1] Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
关键词
lymphoproliferative disorder; Rituximab therapy; transplantation;
D O I
10.1034/j.1399-0012.2003.00054.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Post-transplant lymphoproliferative disorders (PTLD) is a consequence of Epstein - Barr virus (EBV) infection and is a B-cell hyperplasia with CD-20 positive lymphocytes. The treatment of PTLD includes reduction/withdrawal of immunosuppression and chemotherapy. This study reports our center experience with humanized monoclonal antibody against CD-20 ( Rituximab) for the treatment of PTLD. Material and methods: Eight cases of PTLD after solid organ transplantation [ six kidney, one kidney/pancreas (KP) and one liver] occurred between September 1998 and October 2001. The mean time between transplant and the diagnosis of PTLD was 57.3 months ( range 3 months to 10 yr). Five patients underwent cadaveric transplant, five males and six were Caucasians with mean age of 48 yr ( range 20 - 67 yr). Results: The clinical presentation was as follows: lymphadenopathy-5, gastrointestinal bleeding-2 and tonsillar enlargement-1. The diagnosis was made by a lymph node biopsy in five, a gastric ulcer biopsy in two and a tonsillar biopsy in one case. Six of them had polymorphous, two had monoclonal B-cell lymphoma, and all were positive for CD-20. Six were related to EBV, documented by latent membrane protein (LMP) or Epstein - Barr encoded RNA ( EBER) staining. Immunosuppression at the time of PTLD diagnosis consisted of tacrolimus in six cases and cyclosporine A (CsA) in two with mycophenolate mofetil (MMF) and azathioprine-3 each and sirolimus-1. Rituximab was administered at a dose of 375 mg/m(2) once a week for 4 wk. There were no side effects seen with this therapy. Immunosuppression was reduced in all patients. Complete remission was observed in seven cases ( one required two courses). One patient who did not respond received chemotherapy. Patients were followed for a mean period of 22.5 months ( range 10 - 45 months post-PTLD diagnosis. At the last follow-up all eight patients were alive, seven with a functioning graft and one on maintenance dialysis. Three of these patients had been in remission for more than 2.5 yr. Conclusion: Rituximab is an effective agent in the treatment of PTLD without the morbidity characteristic of chemotherapy. Chemotherapy should be reserved only for those refractory to Rituximab therapy.
引用
收藏
页码:417 / 422
页数:6
相关论文
共 18 条
[1]   Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].
Benkerrou, M ;
Jais, JP ;
Leblond, V ;
Durandy, A ;
Sutton, L ;
Bordigoni, P ;
Garnier, JL ;
Le Bidois, J ;
Le Deist, F ;
Blanche, S ;
Fischer, A .
BLOOD, 1998, 92 (09) :3137-3147
[2]   ANTI-B-CELL MONOCLONAL-ANTIBODIES IN THE TREATMENT OF SEVERE B-CELL LYMPHOPROLIFERATIVE SYNDROME FOLLOWING BONE-MARROW AND ORGAN-TRANSPLANTATION [J].
FISCHER, A ;
BLANCHE, S ;
LEBIDOIS, J ;
BORDIGONI, P ;
GARNIER, JL ;
NIAUDET, P ;
MORINET, F ;
LEDEIST, F ;
FISCHER, AM ;
GRISCELLI, C ;
HIRN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1451-1456
[3]   EPSTEIN-BARR VIRUS, IMMUNODEFICIENCY, AND B-CELL LYMPHOPROLIFERATION [J].
HANTO, DW ;
FRIZZERA, G ;
GAJLPECZALSKA, KJ ;
SIMMONS, RL .
TRANSPLANTATION, 1985, 39 (05) :461-472
[4]   RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY [J].
KAMINSKI, MS ;
ZASADNY, KR ;
FRANCIS, IR ;
MILIK, AW ;
ROSS, CW ;
MOON, SD ;
CRAWFORD, SM ;
BURGESS, JM ;
PETRY, NA ;
BUTCHKO, GM ;
GLENN, SD ;
WAHL, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (07) :459-465
[5]   Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease [J].
Manez, R ;
Breinig, MC ;
Linden, P ;
Wilson, J ;
TorreCisneros, J ;
Kusne, S ;
Dummer, S ;
Ho, M .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1462-1467
[6]   Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients [J].
Milpied, N ;
Vasseur, B ;
Parquet, N ;
Garnier, JL ;
Antoine, C ;
Quartier, P ;
Carret, AS ;
Bouscary, D ;
Faye, A ;
Bourbigot, B ;
Reguerre, Y ;
Stoppa, AM ;
Bourquard, P ;
de Ligny, BH ;
Dubief, F ;
Mathieu-Boue, A ;
Leblond, V .
ANNALS OF ONCOLOGY, 2000, 11 :113-116
[7]   Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation - A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? [J].
Oertel, SHK ;
Anagnostopoulos, I ;
Bechstein, WO ;
Liehr, H ;
Riess, HB .
TRANSPLANTATION, 2000, 69 (03) :430-432
[8]   Are post-transplant lymphomas inevitable? [J].
Opelz, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (10) :1952-1955
[9]   CANCERS COMPLICATING ORGAN-TRANSPLANTATION [J].
PENN, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (25) :1767-1769
[10]   TREATMENT OF SEVERE EPSTEIN-BARR VIRUS-INDUCED LYMPHOPROLIFERATIVE SYNDROME WITH GANCICLOVIR - 2 CASES AFTER SOLID ORGAN-TRANSPLANTATION [J].
PIRSCH, JD ;
STRATTA, RJ ;
SOLLINGER, HW ;
HAFEZ, GR ;
DALESSANDRO, AM ;
KALAYOGLU, M ;
BELZER, FO .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (02) :241-244